Raymond James Financial
SLNO

Raymond James Financial’s Soleno Therapeutics SLNO Stock Holding History

Raymond James Financial’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-298
Closed -$25K – 6486
2025
Q2 		$25K Buy
+298
New +$22.3K ﹤0.01% 5504

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James Financial's SLNO Position: Q3 2025 in Review

Raymond James Financial sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 298 shares — an estimated $25K sold.

Raymond James Financial first reported a position in SLNO in Q2 2025 and held it in 1 quarter. The position peaked at $25K in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Raymond James Financial reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 298 Soleno Therapeutics shares in Q3 2025, an estimated $25K.
  • Raymond James Financial first reported a position in Soleno Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Soleno Therapeutics position peaked at $25K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.